Altimmune, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:ALT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 157.26 M190.35 M218.45 M279.93 M335.63 M Total liabilities 15.1 M28.98 M32.85 M55.04 M51.64 M Total equity 142.16 M161.37 M185.6 M224.89 M283.99 M Total liabilities & shareholders' equities 157.26 M190.35 M218.45 M279.93 M335.63 M Total debt —14.33 M14.45 M34.29 M34.51 M Net debt —14.33 M14.45 M34.29 M34.51 M

News

After US-Iran Ceasefire 'Ends', Crypto and Stock Markets Suffer Widespread Declines

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade (ALT)

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

5 Small Drug Stocks to Invest in Amid a Biotech Comeback

Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

ALT and the Rise of Dual Agonists Targeting Liver Disease

ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

GLP-1 Sales Forecast Jumps To $150 Billion By 2030

Here's Why You Should Add Altimmune Stock to Your Portfolio Now

Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil